Activation of N-methyl-D-aspartate (NMDA) receptors in the dorsal vagal complex lowers glucose production.
Diabetes is characterized by hyperglycemia due partly to increased hepatic glucose production. The hypothalamus regulates hepatic glucose production in rodents. However, it is currently unknown whether other regions of the brain are sufficient in glucose production regulation. The N-methyl-D-aspartate (NMDA) receptor is composed of NR1 and NR2 subunits, which are activated by co-agonist glycine and glutamate or aspartate, respectively. Here we report that direct administration of either co-agonist glycine or NMDA into the dorsal vagal complex (DVC), targeting the nucleus of the solitary tract, lowered glucose production in vivo. Direct infusion of the NMDA receptor blocker MK-801 into the DVC negated the metabolic effect of glycine. To evaluate whether NR1 subunit of the NMDA receptor mediates the effect of glycine, NR1 in the DVC was inhibited by DVC NR1 antagonist 7-chlorokynurenic acid or DVC shRNA-NR1. Pharmacological and molecular inhibition of DVC NR1 negated the metabolic effect of glycine. To evaluate whether the NMDA receptors mediate the effects of NR2 agonist NMDA, DVC NMDA receptors were inhibited by antagonist D-2-amino-5-phosphonovaleric acid (D-APV). DVC D-APV fully negated the ability of DVC NMDA to lower glucose production. Finally, hepatic vagotomy negated the DVC glycine ability to lower glucose production. These findings demonstrate that activation of NR1 and NR2 subunits of the NMDA receptors in the DVC is sufficient to trigger a brain-liver axis to lower glucose production, and suggest that DVC NMDA receptors serve as a therapeutic target for diabetes and obesity.
Lam
Carol K L
CK
Toronto General Research Institute, University Health Network, Toronto M5G 1L7, Canada.
Chari
Madhu
M
Su
Brenda B
BB
Cheung
Grace W C
GW
Kokorovic
Andrea
A
Yang
Clair S
CS
Wang
Penny Y T
PY
Lai
Teresa Y Y
TY
Lam
Tony K T
TK
D015763:2-Amino-5-phosphonovalerate / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D055785:Gene Knockdown Techniques; D005947:Glucose / Q000096:biosynthesis*; D005998:Glycine / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D007736:Kynurenic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D008099:Liver / Q000187:drug effects / Q000294:innervation / Q000378:metabolism; D008297:Male; D016202:N-Methylaspartate / Q000494:pharmacology; D021122:Protein Subunits / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014628:Vagotomy; D014630:Vagus Nerve / Q000187:drug effects / Q000378:metabolism*
C409466:NR1 NMDA receptor; C120997:NR2A NMDA receptor; D021122:Protein Subunits; D016194:Receptors, N-Methyl-D-Aspartate; D016202:N-Methylaspartate; D015763:2-Amino-5-phosphonovalerate; D007736:Kynurenic Acid; D005947:Glucose; C057013:7-chlorokynurenic acid; D005998:Glycine
Nat Neurosci. 2002 Nov;5 Suppl:1039-42
12403981
Physiol Rev. 1994 Jul;74(3):723-60
8036251
Science. 2005 Jan 21;307(5708):375-9
15662002
Nature. 2002 Feb 14;415(6873):793-8
11823786
Neurosci Lett. 1992 Feb 3;135(2):265-8
1625808
Nature. 2001 May 31;411(6837):587-90
11385573
J Neurosci. 2003 Jun 15;23(12):5031-40
12832526
Cell. 2007 Apr 20;129(2):251-62
17448988
Cell Metab. 2007 Aug;6(2):99-104
17681145
Crit Rev Neurobiol. 2004;16(3):187-224
15701057
Science. 1988 Aug 12;241(4867):835-7
2841759
Brain Res. 2001 Aug 10;910(1-2):192-4
11489271
Neuron. 1994 Aug;13(2):325-38
8060614
Nature. 2008 Apr 24;452(7190):1012-6
18401341
Diabetes. 2008 Apr;57(4):836-40
18184925
J Pharmacol Exp Ther. 2005 Feb;312(2):834-40
15388787
Neuron. 2008 May 22;58(4):472-97
18498731
Cell Metab. 2006 Apr;3(4):267-75
16581004
Nature. 2005 Apr 21;434(7036):1026-31
15846348
J Clin Invest. 2005 Mar;115(3):703-10
15711637
J Neurochem. 1977 Aug;29(2):291-7
886334
Nat Rev Neurosci. 2008 Jul;9(7):519-31
18509340
Nat Med. 2002 Dec;8(12):1376-82
12426561
Cell. 1999 Apr 2;97(1):9-12
10199397
Cell Metab. 2007 Jun;5(6):438-49
17550779
J Pharmacol Exp Ther. 2007 Sep;322(3):982-8
17551091
Cell Metab. 2006 Jan;3(1):67-73
16399506
Obesity (Silver Spring). 2006 Aug;14 Suppl 5:216S-221S
17021370
Physiology (Bethesda). 2009 Jun;24:159-70
19509126
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15730-4
9861038
Cell Metab. 2009 Aug;10(2):99-109
19656488
J Neurophysiol. 2005 Jul;94(1):147-52
15744010
Nat Med. 2010 Apr;16(4):392-5
20376051
Science. 2005 Aug 5;309(5736):943-7
16081739
J Clin Invest. 2007 Jan;117(1):13-23
17200702
Mol Pharmacol. 2007 Oct;72(4):907-20
17622578
Cell Metab. 2006 Aug;4(2):123-32
16890540
Nature. 2006 Sep 21;443(7109):289-95
16988703
Nat Med. 2003 Jun;9(6):756-61
12754501
Diabetes. 2008 Aug;57(8):2061-5
18511848